Brief: Index Pharmaceuticals Advances Cobitolimod Further Towards Phase III

Flerie AB

16/04/2020 12:33

April 16 (Reuters) - InDex Pharmaceuticals Holding AB
 INDEX.ST :
    * INDEX PHARMACEUTICALS ADVANCES COBITOLIMOD FURTHER TOWARDS
PHASE
III FOLLOWING SUCCESSFUL INTERACTIONS WITH FDA AND EMA
    * INDEX PHARMACEUTICALS HOLDING AB - HAS RECEIVED POSITIVE
RESPONSES FROM FDA AND EMA REGARDING PHASE III DEVELOPMENT OF
COMPANY'S TLR9 AGONIST COBITOLIMOD, FOR TREATMENT OF MODERATE TO
SEVERE ULCERATIVE COLITIS
    * INDEX PHARMACEUTICALS HOLDING AB - COMPANY IS CONTINUING
ITS
PHASE III PREPARATIONS, INCLUDING EFFORTS TO SECURE FINANCING.
    * INDEX PHARMACEUTICALS HOLDING AB - GIVEN CURRENT LEVEL OF
ACTIVITY AND FINANCIAL COMMITMENTS, CASH AND CASH EQUIVALENTS,
WHICH AT MARCH 31 AMOUNTED TO JUST OVER SEK 100 MILLION, ARE
SUFFICIENT TO FINANCE BUSINESS FOR AT LEAST 12 MONTHS

Source text for Eikon:  ID:nWkr3Xp98J 
Further company coverage:  INDEX.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))